eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | retinal vein occlusion |
| Symptom | |macular edema |
| Sentences | 187 |
| PubMedID- 25371633 | Purpose: to evaluate the anatomical and functional efficacy of combination therapy of intravitreal ranibizumab with laser or intravitreal bevacizumab with laser treatment compared to only laser treatment for macular edema due to branch retinal vein occlusion (brvo). |
| PubMedID- 20103055 | Methods: ninety-one eyes of 91 patients with macular edema associated with retinal vein occlusion had undergone a comprehensive ophthalmologic examination, including measurement by spectral-domain oct. |
| PubMedID- 21629578 | Treatment of macular edema due to retinal vein occlusions. |
| PubMedID- 24332373 | Study population: thirteen eyes of 13 treatment-naive patients undergoing serial intravitreal anti-vascular endothelial growth factor (vegf) injections for exudative age-related macular degeneration or macular edema attributable to retinal vein occlusion. |
| PubMedID- 25371814 | Long-term outcome after vitrectomy for macular edema with retinal vein occlusion dividing into the occlusion site. |
| PubMedID- 22823029 | Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (vegf), is widely used for the treatment of macular edema associated with central retinal vein occlusion (crvo). |
| PubMedID- 21805173 | Association of electroretinogram and morphological findings in branch retinal vein occlusion with macular edema. |
| PubMedID- 23510041 | Background and objective: to evaluate the influence of serous retinal detachment (srd) on the outcome of pars plana vitrectomy (ppv) for macular edema in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 21750607 | Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results. |
| PubMedID- 26366053 | Purpose: to evaluate the differences in the development of collateral vessels in patients with macular edema due to branch retinal vein occlusion (brvo) after treatment with either grid laser or ranibizumab (rnb). |
| PubMedID- 25902119 | Patients and methods: we describe a retrospective series of patients followed in the medical retina unit of the jules gonin eye hospital for macular edema due to ischemic central retinal vein occlusion, refractory to monthly retreatment with ranibizumab, and changed to aflibercept. |
| PubMedID- 24884703 | Role of inflammation in previously untreated macular edema with branch retinal vein occlusion. |
| PubMedID- 22988344 | Ozurdex received fda approval in june 2009 for the treatment of macular edema associated with retinal vein occlusion, and in september 2010, it became the second fda-approved therapeutic agent for the treatment of noninfectious posterior uveitis.in a 26-week, multicenter, double-masked, randomized clinical study in which 229 patients were randomized in a 1 : 1 : 1 ratio receiving 0.70 mg ozurdex (n = 77), 0.35 mg ozurdex (n = 76), or sham injection (n = 76). |
| PubMedID- 25300393 | Purpose: to evaluate the early effects of the intravitreal erodible dexamethasone implant ozurdex in patients with macular edema due to retinal vein occlusion (rvo). |
| PubMedID- 20935688 | Visual improvement in established central retinal vein occlusion with long-standing macular edema following systemic eculizumab treatment. |
| PubMedID- 21191716 | Visual acuity following intravitreal bevacizumab for macular edema associated with retinal vein occlusion. |
| PubMedID- 24999721 | Methods: a retrospective review of six consecutive cases of central retinal vein occlusion with persistent macular edema despite regular anti-vascular endothelial growth factor injections that were transitioned to aflibercept was conducted. |
| PubMedID- 24104718 | We report three patients of retinal vein occlusion with macular edema who demonstrated overnight resolution of macular edema following treatment with intravitreal ranibizumab (0.5 mg). |
| PubMedID- 25384627 | Photopic negative response in branch retinal vein occlusion with macular edema. |
| PubMedID- 23629792 | Background: the effect of bevacizumab (be) (avastin(r)) or ranibizumab (ra) (lucentis(r)) on the visual acuity (va) and on the central foveal thickness (cft) was evaluated in macular edema due to retinal vein occlusion. |
| PubMedID- 24330936 | There is an urgent requirement to find effective therapeutic procedures for the treatment of refractory eye diseases of posterior segment such as posterior uveitis, proliferative vitreoretinopathy, and macular edema associated with diabetes and retinal vein occlusion. |
| PubMedID- 23709332 | Macular pseudohole development after sustained-release dexamethasone intravitreal implant for macular edema due to central retinal vein occlusion. |
| PubMedID- 20429890 | Conclusions: these results suggest that the vitreous level of vascular endothelial growth factor might influence the visual prognosis and the response of macular edema to vitrectomy in patients with branch retinal vein occlusion. |
| PubMedID- 22304619 | Purpose: to evaluate functional and morphological changes of the macula after intravitreal injection of triamcinolone acetonide (ivta) for macular edema with branch retinal vein occlusion (brvo). |
| PubMedID- 23842103 | Purpose: to evaluate the association between vitreous fluid levels of inflammatory factors and macular edema in patients with central retinal vein occlusion (crvo). |
| PubMedID- 26150834 | Objectives: to evaluate the effects and safety of intravitreal ranibizumab on visual acuity and anatomic results in the treatment of macular edema due to retinal vein occlusion (rvo). |
| PubMedID- 22527327 | Background: the purpose of this study was to compare the efficacy of intravitreal ranibizumab in the treatment of macular edema due to branch retinal vein occlusions (brvo) with and without serous macular neuroretinal detachment (smd). |
| PubMedID- 23629796 | Conclusion: our study showed efficacy and safety of intravitreal dexamethasone implant in the treatment of macular edema due to retinal vein occlusion. |
| PubMedID- 23225839 | Methods: eighty-nine eyes with macular edema associated with retinal vein occlusion first received periocular injection of 40 mg triamcinolone acetonide (ta) and were followed for one month. |
| PubMedID- 25347799 | Effect of intravitreal injection of dexamethasone implant on corneal endothelium in macular edema due to retinal vein occlusion. |
| PubMedID- 22392532 | It is an fda-approved intravitreal therapy for the treatment of age-related macular degeneration and macular edema associated with retinal vein occlusion . |
| PubMedID- 21468337 | Scott et al23 demonstrated that the correlation between oct-measured center point thickness, and visual acuity letter score was statistically significant, but this relationship was, at best, modest in patients with macular edema associated with retinal vein occlusions. |
| PubMedID- 23044946 | Management of macular edema associated with retinal vein occlusion. |
| PubMedID- 21337042 | Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. |
| PubMedID- 23154502 | Purpose: to evaluate the long-term visual prognosis and complications of patients who received intravitreal ozurdex injections for the treatment of macular edema (me) due to retinal vein occlusion (rvo). |
| PubMedID- 22153634 | Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (lucentis). |
| PubMedID- 20182882 | Purpose: to compare visual outcomes after intravitreal triamcinolone acetonide (ivta) injection and intravitreal bevacizumab (ivb) administration for treatment of macular edema associated with branch retinal vein occlusion (brvo). |
| PubMedID- 22140307 | As a result of recent clinical trials, the 0.7 mg dexamethasone sustained release intravitreal implant has been fda approved for both the treatment of macular edema due to retinal vein occlusions and also for the treatment of noninfectious, posterior uveitis. |
| PubMedID- 23972086 | Purpose/aim: the aqueous humor level of soluble vascular endothelial growth factor receptor (svegfr)-2 may influence macular edema in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 24894397 | Purpose: to evaluate the association between multiple factors in aqueous humor and the severity of macular edema in patients with branch retinal vein occlusion (brvo). |
| PubMedID- 21350277 | A comparative study between intravitreal triamcinolone and bevacizumab for macular edema due to central retinal vein occlusion with poor vision. |
| PubMedID- 21911591 | Purpose: to study the usefulness of focal macular electroretinography (fmerg) for evaluation of macular function in eyes with macular edema (me) associated with branch retinal vein occlusion (brvo). |
| PubMedID- 26425104 | Aflibercept has been approved by the united states food and drug administration (fda) for the treatment of neovascular amd and macular edema due to retinal vein occlusions. |
| PubMedID- 23539479 | The influence of retinal ischemia on changes of visual acuity, macular sensitivity, macular thickness, and macular volume is unclear after pars plana vitrectomy (ppv) for macular edema with branch retinal vein occlusion (brvo). |
| PubMedID- 25657578 | Comparison of single injection and three monthly injections of intravitreal bevacizumab for macular edema associated with branch retinal vein occlusion. |
| PubMedID- 26501219 | The primary treatment against macular edema with retinal vein occlusion (rvo) has changed from observation in central rvo (crvo) and laser photocoagulation in branch rvo (brvo) to administration of intravitreal agents based on anti-vascular endothelial growth factor (vegf) or anti-inflammatory strategies. |
| PubMedID- 21726846 | Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion. |
| PubMedID- 19430731 | We report a case of a 69-year-old male patient who came to our attention for macular edema in hemiretinal vein occlusion. |
| PubMedID- 22095093 | Retinal sensitivity after resolution of the macular edema associated with retinal vein occlusion. |
| PubMedID- 25634982 | Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema. |